Europe Carrier Screening Market

Europe Carrier Screening Market Size (2023 to 2028)

The carrier screening market size in Europe is projected to be valued at USD 0.94 billion by 2028 from USD 0.6 billion in 2023, growing at a CAGR of 9.27% from 2023 to 2028.

The increasing prevalence of genetic disorders in Europe majorly drives the growth of the Europe carrier screening market. Approximately 4% of children in Europe are affected by genetic disorders which highlights the need for effective screening measures. Carrier screening plays a crucial role in identifying the risk of genetic disorders in children by assessing both parents' genetic profiles. With growing awareness among the population, parents are actively seeking information about their genetic background and potential risks to their offspring. By undergoing carrier screening tests, parents can make informed decisions and take preventive measures to mitigate the chances of genetic disorders in their children. This not only helps individuals and families make informed choices but also contributes to reducing the overall burden of genetic conditions in the population. Additionally, carrier screening is a valuable tool for couples planning for pregnancy, allowing them to assess their genetic compatibility and make informed decisions about conceiving. By addressing the needs of individuals and couples at risk of genetic conditions, the carrier screening market in Europe experiences significant growth and plays a vital role in ensuring healthier outcomes for future generations.

The growing number of technical advancements in carrier screening further boosts the growth rate of the European market growth. Next Generation Sequencing (NGS) plays a crucial role in conducting comprehensive and accurate carrier screening by analyzing specific genes. The continuous progress in molecular technology further contributes to the development of carrier screening to enable researchers and healthcare professionals to obtain precise and reliable results. With a focus on innovation and improvement, manufacturers are actively developing advanced equipment and devices to support carrier screening processes. These advancements not only enhance the efficiency and accuracy of carrier screening but also facilitate the identification of potential genetic disorders at an early stage. Moreover, the increasing investment in research and development, robust infrastructure facilities, support from pharmaceutical companies, and government initiatives play pivotal roles in driving the growth of the carrier screening market. By harnessing these advancements and collaborative efforts, the Europe market for carrier screening continues to expand, enabling individuals and families to make informed decisions regarding their genetic health.

The high cost associated with carrier screening tests in Europe significantly hampers the market growth in the Europe region. Factors such as the shortage of skilled professionals, inadequate infrastructure, limited awareness about carrier screening and stringent government regulations limit the market's growth rate in Europe. The emotional tension experienced by individuals undergoing carrier screening and the anxiety among families further impedes the market growth.

This research report on the Europe carrier screening market has been segmented and sub-segmented into the following categories.

By Type:

• Molecular Screening Test
• Biochemical Screening Test

By Technology:

• DNA Sequencing
• Polymerase Chain Reaction
• Microarray

By End-User:

• Hospitals
• Reference Laboratories
• Physician Offices & Clinics

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The Europe region holds a prominent position in the worldwide market and will grow at a noteworthy CAGR during the forecast period owing to the growing number of advancements in screening technology, increased awareness about early diagnosis and government initiatives promoting accessibility to screening procedures. The UK held the major share of the European market in 2022 and is likely to continue its domination in the European market during the forecast period owing to the presence of numerous screening laboratories and clinical trial centers. These laboratories play a crucial role in understanding the genetic structure and identifying solutions for the treatment process. Additionally, carrier tests are conducted in the country to detect rare diseases among patients. Germany is predicted to hold a considerable share of the European market during the forecast period. In Germany, the market is supported by collaborations between healthcare organizations and key players, as well as the implementation of carrier tests by certified physicians following the German Gene Diagnostics Law. Strict adherence to regulations and the presence of clinics and hospitals specializing in carrier screening further contribute to market growth. The demand for carrier screening is also driven by the adoption of personalized medicine by the population.

KEY MARKET PLAYERS:

Abbott Laboratories, 23Andme Inc., Autogenomics Inc., Danaher Corporation, Fulgent Genetics Inc., Myriad Genetics, Opko Health, Quest Diagnostics Incorporated, Eurofins Scientific, Illumina Inc., Luminex Corporation, Invitae Corporation, MedGenome, Natera Inc., Thermo Fisher Scientific Inc., Roche AG, Sequenom Inc., and True Health are some of the notable companies in the European carrier screening market.